Imaging Synaptic Vesicle Protein SV2C with 18F-UCB-F: An In Vitro Autoradiography and In Vivo NHP PET Study

Although [18F]UCB-F demonstrates specific binding to SV2C in vitro autoradiography, its rapid in vivo radiometabolism and temperature-dependent affinity loss result in poor brain retention and lack of specific binding in non-human primates, rendering it unsuitable as a PET radioligand for imaging SV2C.

The Gist

The Big Picture: Looking for a "Lost Key" in the Brain

Imagine your brain is a bustling city, and the basal ganglia (a specific neighborhood in the city) is where the traffic lights for movement are controlled. In Parkinson's disease, these traffic lights start to flicker and fail.

Scientists have discovered a specific protein called SV2C that acts like a crucial "traffic controller" in this neighborhood. It helps release dopamine, the chemical that keeps movement smooth. When SV2C is broken or missing, the city gets gridlocked (Parkinson's symptoms).

The goal of this study was to build a special molecular camera (a radioactive tracer called [18F]UCB-F) that could take a photo of these traffic controllers (SV2C) inside a living brain. If they could take a clear photo, doctors could see exactly how much damage Parkinson's has done and check if new medicines are working.

The Experiment: The "Test Drive"

The researchers tried to use this new camera in two different ways:

1. The "Static" Test (In Vitro): They took slices of brain tissue from rats and monkeys, put them on a table, and sprayed the camera on them.

   • The Result: It worked perfectly! The camera stuck exactly where the traffic controllers were. It was like taking a high-resolution photo of a map; the details were clear.

2. The "Live" Test (In Vivo): They injected the camera into the bloodstream of live monkeys and watched it with a PET scanner (a special camera that sees inside the body).

   • The Result: It was a disaster. The camera rushed into the brain, but then it immediately washed out. It didn't stick to anything. The resulting image was just a blurry, empty fog. It was like trying to take a photo of a moving car with a camera that only stays focused for a split second before the shutter jams.

Why Did It Fail? (The "Hot vs. Cold" Mystery)

The scientists were puzzled. Why did it work on the table but fail in the living body? They found two main culprits:

1. The "Goldilocks" Temperature Problem
The camera was designed to stick to the protein, but it only stuck well when it was cold (like a refrigerator at 4°C).

• The Analogy: Imagine trying to stick a piece of tape to a wall. It sticks great in a cold room. But if you turn up the heat to body temperature (37°C), the glue melts, and the tape falls off.
• The Science: The researchers used computer simulations to see why. They found that the "glue" holding the camera to the protein is a tiny hydrogen bond. At cold temperatures, this bond is strong and stable. At body temperature, the bond vibrates so much it breaks, and the camera lets go.

2. The "Fast-Forward" Metabolism
Even if the camera had managed to stick, the monkey's body was too fast for it.

• The Analogy: Imagine you send a spy into a city to deliver a message. But the city's security guards (the liver and blood enzymes) are so efficient that they catch the spy and turn him into a generic civilian within 15 minutes. By the time the spy reaches the important building, he's no longer the spy; he's just a random person.
• The Science: The monkey's body broke down the radioactive camera so quickly that only about 15% of it was still in its original form after 15 minutes. The rest was just "trash" (metabolites) that couldn't take a picture.

The Conclusion: Back to the Drawing Board

The study concluded that [18F]UCB-F is a failed candidate for imaging Parkinson's disease in living humans.

• What went right: They proved the chemistry works on a table, and they successfully built the camera.
• What went wrong: The camera is too sensitive to heat (it falls off at body temperature) and gets destroyed too fast by the body.

The Takeaway:
Think of this like a car manufacturer testing a new sports car. They put it on a test track (the lab slices), and it drives beautifully. But when they take it out on the real highway (the living body), the engine overheats and the tires blow out.

The researchers are now going back to the drawing board to design a new camera that has "stronger glue" (so it stays stuck at body temperature) and is "tougher" (so the body doesn't break it down so fast). Until then, we don't have a working camera to see SV2C in Parkinson's patients.

Technical Summary

1. Problem Statement

Synaptic Vesicle Protein 2C (SV2C) is a critical regulator of dopamine release, predominantly expressed in the basal ganglia. Genetic and pathological studies link SV2C disruption to Parkinson's disease (PD), making it a promising target for Positron Emission Tomography (PET) imaging to monitor synaptic dysfunction and disease progression.

However, developing a specific PET radioligand for SV2C is challenging due to:

• Low density: SV2C has a much lower expression level than the ubiquitous SV2A.
• Selectivity requirements: A candidate must bind SV2C with high affinity while showing negligible binding to SV2A and SV2B.
• Pharmacokinetic hurdles: The ligand must possess suitable brain penetration and metabolic stability.

[18F]UCB-F, developed by UCB, showed promising distribution patterns in in vitro autoradiography (matching SV2C expression) but failed to demonstrate specific binding in in vivo rat PET studies. The primary objective of this study was to investigate the reasons for this discrepancy and evaluate [18F]UCB-F as a candidate for Non-Human Primate (NHP) PET imaging.

2. Methodology

The study employed a multi-modal approach combining computational modeling, radiochemistry, in vitro binding assays, and in vivo NHP PET imaging.

• In Silico Modeling:
  • Homology modeling of SV2C was performed using SV2A (PDB: 8UO9) as a template.
  • Molecular Dynamics (MD) simulations were conducted at three temperatures (277 K, 294 K, and 310 K) to analyze the stability of the UCB-F–SV2C complex, specifically focusing on hydrogen bond lifetimes and Root Mean Square Deviation (RMSD).
• Radiochemistry:
  • [18F]UCB-F was synthesized via nucleophilic substitution of a mesylate precursor using [18F]fluoride, Kryptofix 2.2.2, and K2CO3 in acetonitrile at 100°C.
  • Purification was achieved via HPLC and Solid-Phase Extraction (SPE), yielding >99% radiochemical purity.
• In Vitro Autoradiography:
  • Performed on brain slices from Sprague Dawley rats (12 µm) and cynomolgus monkeys (20 µm).
  • Specific binding was assessed by comparing total binding against non-specific binding (co-incubated with 10 µM cold UCB-F).
• In Vitro Competition Binding:
  • Affinity ($pK_i$) for SV2A, SV2B, and SV2C was measured at both 4°C and 37°C to assess temperature dependence.
• In Vivo NHP PET:
  • Two cynomolgus monkeys underwent dynamic PET scans (123 min) following bolus injection of [18F]UCB-F.
  • Regions of Interest (VOIs) included the striatum, globus pallidus, substantia nigra, and cerebellum.
  • Blood samples were collected for radiometabolite analysis to determine the fraction of unchanged parent compound in plasma.

3. Key Contributions

• First NHP Evaluation: This is the first study to evaluate [18F]UCB-F in Non-Human Primates, providing a more clinically relevant model than rodents.
• Temperature-Dependent Affinity Discovery: The study definitively characterized the drastic drop in SV2C affinity for UCB-F as temperature increases from 4°C to 37°C.
• Mechanistic Insight via MD: The authors provided a structural explanation for the affinity loss, linking it to the destabilization of key hydrogen bonds at physiological temperatures.
• Metabolic Profile: Detailed characterization of the rapid metabolism of [18F]UCB-F in NHP plasma.

4. Results

A. In Silico Modeling

• MD simulations confirmed that UCB-F adopts a stable binding pose at lower temperatures.
• Hydrogen Bond Instability: At 277 K (4°C), a key hydrogen bond had a mean lifetime of 11.86 ns. At 310 K (37°C), this lifetime dropped to 1.03 ns. This suggests that thermal energy disrupts the specific interactions required for high-affinity binding.

B. In Vitro Binding & Autoradiography

• Autoradiography: [18F]UCB-F showed specific binding in rat and NHP brain slices, with high uptake in the basal ganglia (striatum, globus pallidus, substantia nigra) and brainstem, consistent with SV2C expression. Non-displaceable binding was low (<10-20%).
• Competition Binding (Temperature Effect):
  • At 4°C: High affinity for SV2C ($pK_i \approx 8.4$).
  • At 37°C: Affinity dropped significantly to $pK_i \approx 6.8–7.3$ (a decrease of ~1 order of magnitude).
  • Selectivity: At 37°C, the ligand maintained selectivity over SV2A and SV2B ($pK_i < 6$), but the absolute affinity for SV2C was too low for effective in vivo imaging.

C. In Vivo PET (NHP)

• Brain Uptake: The tracer crossed the blood-brain barrier rapidly, peaking at ~3.0–3.4 SUV at 4 minutes.
• Kinetics: The tracer exhibited rapid washout from all brain regions with no discernible regional differences in retention.
• Outcome: No specific binding signal was detected in vivo, contrasting sharply with the in vitro autoradiography results.

D. Radiometabolite Analysis

• [18F]UCB-F was rapidly metabolized in NHP plasma.
• The percentage of unchanged parent compound dropped from 92% at 2 minutes to **2% at 45 minutes**.
• Metabolites were more polar than the parent compound, suggesting they likely do not cross the blood-brain barrier or contribute to specific binding.

5. Significance and Conclusion

Conclusion:
The study concludes that [18F]UCB-F is not a suitable PET radioligand for imaging SV2C in vivo.

Reasoning:
The discrepancy between successful in vitro autoradiography and failed in vivo PET is attributed to two main factors:

1. Temperature-Dependent Affinity: The high affinity observed in in vitro assays (often conducted at 4°C or room temperature) does not translate to physiological conditions (37°C). The hydrogen bonds stabilizing the ligand-protein complex are too weak at body temperature, leading to rapid dissociation.
2. Rapid Metabolism: The tracer is cleared from the plasma too quickly (only ~15% unchanged at 15 min), preventing sufficient accumulation and retention in the brain to allow for specific binding quantification.

Impact:
This work highlights the critical importance of validating radioligand affinity at physiological temperatures (37°C) rather than relying solely on in vitro data obtained at lower temperatures. It also underscores the need for future SV2C ligands to possess both higher thermal stability in binding and improved metabolic stability to be viable for clinical PET imaging of Parkinson's disease and other synaptic disorders.